Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Fusen Pharmaceutical Co. Ltd. has announced the acceptance of their Phase II clinical trial application for SY617, an innovative traditional Chinese medicine aimed at treating influenza with promising prospects. SY617, which targets symptoms of wind-heat with dampness syndrome, strengthens the company’s anti-flu product line and offers a fresh treatment alternative amidst the RMB 8.5 billion traditional Chinese cold medicine market. This development could provide a significant boost to the company’s portfolio and offer patients more options for flu treatment.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.